



AMENDMENTS TO THE CLAIMS


1. (Currently amended) A pharmaceutical composition for treating ~~or preventing an~~ allergic reaction associated with increased IgE levels ~~or for inhibiting NF- κ B mediated cellular~~ proliferation in a mammal, comprising a compound or salt thereof selected from any of the following formulas:




Genus 1;



Genus 2;



Genus 3; and



Genus 4;

Appl. No. : 10/821,667
Filed : April 9, 2004

wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R₃, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, CN, CF₃, OCF₃, NO₂, COOR'', CHO, and COR'';

wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur, and wherein R₁ and R₂ are not both methyl or phenyl;

wherein substituents of the substituted alkyl, the substituted C₃-C₉ cycloalkyl, the substituted phenyl, the substituted naphthyl and the substituted heterocyclic are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, COOR', COR', CN, CF₃, OCF₃, NO₂, NR'R' and CONR'R';

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; ~~and~~

wherein R'' is selected from the group consisting of C₁-C₉ alkyl, wherein said C₁-C₉ alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl; and

at least a pharmaceutically acceptable diluent.

2. (Previously presented) The pharmaceutical composition of Claim 1, wherein said polycyclic aliphatic group is selected from the group consisting of adamantyl, bicycloheptyl, camphoryl, bicyclo[2,2,2]octanyl, and norbornyl.

Appl. No. : 10/821,667
Filed : April 9, 2004

3. (Previously presented) The pharmaceutical composition of Claim 1, wherein said heterocyclic and said substituted heterocyclic is selected from the group consisting of pyridines, thiazoles, isothiazoles, oxazoles, pyrimidines, pyrazines, furans, thiophenes, isoxazoles, pyrroles, pyridazines, 1,2,3-triazines, 1,2,4-triazines, 1,3,5-triazines, pyrazoles, imidazoles, indoles, quinolines, iso-quinolines, benzothiophenes, benzofurans, parathiazines, pyrans, chromenes, pyrrolidines, pyrazolidines, imidazolidines, morpholines, thiomorpholines, and the corresponding saturated heterocyclics.

4. (Currently amended) The pharmaceutical composition of Claim 1, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction ~~and/or said cellular proliferation~~.

5. (Withdrawn-currently amended) A method for treating ~~or preventing~~ an allergic reaction in a mammal wherein said reaction is caused by an increase in IgE levels comprising administering an IgE-suppressing amount of at least one compound of Claim 1.

6. (Withdrawn) The method of Claim 5 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

7. (Withdrawn) The method of Claim 6, wherein said at least one additional ingredient is selected from the group consisting of a short-acting β_2 -adrenergic agonist, a long-acting β_2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

8. (Withdrawn-currently amended) The method of Claim 6, wherein said at least one additional ingredient is combined with said at least one IgE-suppressing compound in said pharmaceutically acceptable diluent and co-administered to the mammal.

9. (Withdrawn) The method of Claim 8, wherein said at least one IgE-suppressing compound is administered at a dose of about 0.01 mg to about 100 mg per kg body weight per day.

10. (Withdrawn) The method of Claim 9, wherein said dose is administered in divided doses at regular periodic intervals.

Appl. No. : **10/821,667**
Filed : **April 9, 2004**

11. (Withdrawn) The method of Claim 10, wherein said regular periodic intervals occur daily.

12. (Withdrawn-currently amended) A method for treating ~~or preventing~~ asthma in a mammal comprising administering an IgE-suppressing amount of at least one compound of Claim 1.

13. (Withdrawn) The method of Claim 12 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said asthma.

14. (Withdrawn) The method of Claim 13, wherein said additional ingredient is selected from the group consisting of a short-acting β_2 -adrenergic agonist, a long-acting β_2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Withdrawn-currently amended) The method of Claim ~~16~~13, wherein said at least one additional ingredient is combined with said at least one compound of Claim 1 in asaid pharmaceutically acceptable diluent and co-administered to the mammal.

20. (Withdrawn) The method of Claim 19, wherein said at least one compound of Claim 1 is administered at a dose of about 0.01 mg to about 100 mg per kg body weight per day.

21. (Withdrawn) The method of Claim 20, wherein said dose is administered in divided doses at regular periodic intervals.


22. (Withdrawn) The method of Claim 21, wherein said regular periodic intervals occur daily.

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)


26. (Previously presented) The pharmaceutical composition of Claim 1, wherein R_1 and R_2 are independently selected from the following:




27. (Withdrawn-currently amended) A method of preparing the compound or salt thereof of Genus 1 as defined in of Claim 1, comprising:

converting a Y-substituted-nitro-benzonitrile to a Y-substituted nitro-benzamidine;


reacting the Y-substituted nitro-benzamidine with X-substituted nitro-phenacyl



reducing the species of the formula **13** to form a species of the formula **14**




acylating the species of the formula 14 to form a species of the formula 15



28. (Withdrawn-currently amended) A method of preparing the compound or salt thereof of Genus 1 as defined in of Claim 1, comprising:


converting a Y-substituted nitro-benzonitrile to a Y-substituted nitro-benzamidine;

reacting the Y-substituted nitro-benzamidine with X-substituted acetamido-




phenacyl halide to form species of the formula 74 ;


hydrolyzing the species of the formula 74 to form a species of the formula




acylating the species of the formula 75 to form a species of the formula 76



reducing the species of the formula 76 to form a species of the formula 77




acylating the species of the formula 77 to form a species of the formula



29. (Withdrawn-currently amended) A method of preparing the compound or salt thereof of Genus 2 as defined in Claim 1, comprising:


converting a Y-substituted-nitro-benzonitrile to a Y-substituted nitro-benzamidine;

reacting the Y-substituted nitro-benzamidine with X-substituted cyano-phenacyl




halide to form a species of the formula **92** ;

reducing the species of the formula **92** to form a species of the formula **93**




acylating the species of the formula **93** and subsequently performing a hydrolysis



to form a species of the formula **94** ; and

aminating the species of the formula **94** to form a species of the formula **95**




30. (Withdrawn-currently amended) A method of preparing the compound or salt thereof of Genus 2 as defined in Claim 1, comprising:


converting a Y-substituted nitro-benzonitrile to a Y-substituted nitro-benzamidine;

converting methyl X-substituted 4-acetyl benzoate to a methyl X-substituted 4-(alpha-bromoacetyl) benzoate;


reacting the Y-substituted nitro-benzamidine with methyl X-substituted 4-(alpha-bromoacetyl) benzoate to form species of the formula **103**



hydrolyzing the species of the formula **103** to form a species of the formula **104**




aminating the species of the following formula **104** to form a species of the



formula **105** ; and

reducing and amidating the formula **105** to form a species of the formula **106**




31. (Withdrawn-currently amended) A method of preparing the compound or salt thereof of Genus 3 as defined in of Claim 1, comprising:

converting a Y-substituted-alkoxycarbonyl-benzonitrile to a Y-substituted alkoxycarbonyl-benzamidine;


reacting the Y-substituted alkoxycarbonyl-benzamidine with X-substituted cyano-

phenacyl halide to form a species of the formula **142**




Appl. No. : 10/821,667
Filed : April 9, 2004


hydrolyzing the species of the formula **142** to form a species of the formula **143**



amidating the species of the formula **143** to form a species of the formula **143a**




hydrolyzing the species of the formula **143a** to form a species of the formula **143b**



; and

amidating the species of the formula **143b** to form a species of the formula **144**




32. (Withdrawn-currently amended) A method of preparing the compound or salt thereof of Genus 4 as defined in of Claim 1, comprising:

converting a Y-substituted-alkoxycarbonyl-benzonitrile to a Y-substituted alkoxycarbonyl-benzamidine;


reacting the Y-substituted alkoxycarbonyl-benzamidine with X-substituted nitro-

phenacyl halide to form a species of the formula **152**




;


reducing the species of the formula **152** to form a species of the formula **153**



acylating the species of the formula **153** to form a species of the formula **154**



amidating the species of the formula **154** to form a species of the formula **155**



33. (Previously presented) A compound selected from the group consisting of:

N-{4-[5-(4-cycloheptylamino-phenyl)-1H-imidazol-2-yl]-phenyl}-
cycloheptylamide,

N-{4-[2-(4-(4-fluorobenzoylamino)-phenyl)-3H-imidazol-4-yl]-phenyl}-4-fluoro-
benzamide,

N-{4-[5-(4-cyclohexylamino-phenyl)-1H-imidazol-2-yl]-phenyl}-
cyclohexylamide,

N-{4-[2-(4-(2,4-dichlorobenzoylamino)-phenyl)-3H-imidazol-4-yl]-phenyl}-2,4-
dichloro-benzamide,

N-{4-[5-(4-(2-methylcyclohexyl)-amino-phenyl)-1H-imidazol-2-yl]-phenyl}-(2-
methylcyclohexyl)-amide,

N-(3-(5-(3-(1-Adamantanamido)phenyl)-1H-imidazol-2-yl)phenyl)-1-
adamantanecarboxamide,

N-(4-(5-(3-(1-Adamantanamido)phenyl)-1H-imidazol-2-yl)phenyl)-1-
adamantanecarboxamide,

N-{4-[5-(4-(2-methylcyclohexyl)-amino-phenyl)-1H-imidazol-2-yl]-phenyl}-(4-
methylcyclohexyl)-amide,

N-(4-(5-(4-adamantylamidophenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

Appl. No. : 10/821,667
Filed : April 9, 2004

N-(4-(5-(4-adamantylamidophenyl)-1H-imidazol-2-yl)phenyl)-4-methylcyclohexanecarboxamide,

N-(4-(5-(4-adamantylamidophenyl)-1H-imidazol-2-yl)phenyl)-2-methylcyclohexanecarboxamide,

N-(4-(5-(4-adamantylamidophenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-adamantylamidophenyl)-1H-imidazol-5-yl)phenyl)cyclohexanecarboxamide,

N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-2-methylcyclohexylamide,

N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptylamide,

4-chloro-N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)benzamide,

3,4-chloro-N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)benzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-adamantylamidophenyl)-1H-imidazol-5-yl)phenyl)-4-methylcyclohexanecarboxamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)benzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-4-fluorobenzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-4-chlorobenzamide,

Appl. No. : 10/821,667
Filed : April 9, 2004

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-3,4-dichlorobenzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-4-methoxybenzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-2,3,4,5,6-pentafluorobenzamide,

N-(4-(2-(4-Adamatylamidophenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(Cyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(2-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(4-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(5-(4-(Cycloheptanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)nicotinamide,

N-(4-(2-(4-(Benzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(2,3,4,5,6-Pentafluorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(3,4-Dichlorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(4-Fluorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(4-Chlorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(4-Methoxybenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(4-Nitrobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

Appl. No. : **10/821,667**
Filed : **April 9, 2004**

N-(4-(2-(4-(1-Adamantanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,

N-(4-(2-(4-(Cyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,

N-(4-(2-(4-(2-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,

N-(4-(2-(4-(4-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,

N-(4-(2-(4-(Nicotinamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,

N-(4-(2-(4-(3,4-Dichlorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,

N-(4-(2-(4-(2,3,4,5,6-Pentafluorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,

N-(4-(2-(4-(Cycloheptanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,

2-Methyl-N-(4-(2-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)cyclohexanecarboxamide,

N-(4-(5-(4-(2-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)nicotinamide,

2-Methyl-N-(4-(2-(4-(4-methylcyclohexanamido)phenyl)-1H-imidazol-5-yl)phenyl)cyclohexanecarboxamide,

N-(4-(5-(4-(2-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,

N-(4-(5-(4-(2-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

N-(4-(5-(4-(pyridin-2-ylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,

N-(4-(5-(4-(pyridin-2-ylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)cyclohexanecarboxamide,

Appl. No. : **10/821,667**
Filed : **April 9, 2004**

N-(4-(5-(4-(cycloheptylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)benzenamide,

N-(4-(5-(4-(cycloheptylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

N-(4-(5-(4-(cycloheptylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,

4-(2-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)-N-cycloheptylbenzamide,

4-(2-(4-(2-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)-N-cycloheptylbenzamide,

4-(2-(4-(adamantylamidophenyl)-1H-imidazol-5-yl)-N-cycloheptylbenzamide,

Adamantane-1-carboxylic acid (4-{5-[4-(adamantan-2-ylcarbamoyl)-phenyl]-1H-imidazol-2-yl}-phenyl)-amide,

N-Adamantan-2-yl-4-[2-[4-(cyclohexanecarbonyl-amino)-phenyl]-3H-imidazol-4-yl]-benzamide,

Cycloheptane carboxylic acid (4-{5-[4-(adamantan-2-ylcarbamoyl)-phenyl]-1H-imidazol-2-yl}-phenyl)-amide,

Pyridine-2-carboxylic acid (4-{5-[4-(adamantan-2-ylcarbamoyl)-phenyl]-1H-imidazol-2-yl}-phenyl)-amide,

N-(4-(5-(4-(Cyclohexylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

N-(4-(2-(4-(Cyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)-N-cyclohexylbenzamide, and

N-(4-(5-(4-(Cyclohexylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide.